Related content

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

By Papp Kim   Ho Vincent   Langley Richard   Lynde Charles   Poulin Yves   Shear Neil   Toole John   Zip Catherine  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 26-32

Springer Publishing Company

Access to resources Recommend Favorite

Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA

By Fernández-Torres Rosa María   Paradela Sabela   Fonseca Eduardo  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 54-56

Informa Healthcare

Access to resources Recommend Favorite

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

By Langley Richard   Ho Vincent   Lynde Charles   Papp Kim   Poulin Yves   Shear Neil   Toole Jack   Zip Catherine  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 18-25

Springer Publishing Company

Access to resources Recommend Favorite

Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States

By Anis Aslam H.   Bansback Nick   Sizto Sonia   Gupta Shiraz R.   Willian Mary K.   Feldman Steve R.  

Journal of Dermatological Treatment, Vol. 22, Iss. 2, 2011-04 ,pp. : 65-74

Informa Healthcare

Access to resources Recommend Favorite